SynthesisArchives of dermatological research2025
Off-label use of JAK1 inhibitor upadacitinib in dermatology.
Synthesis in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Monitoring the Response to JAK Inhibitor Treatment in Alopecia Areata Using Reflectance Confocal Microscopy and Videotrichoscopy: A 60-Week Observational Study.Dermatology and therapy · 2026Article
- Cutaneous and erosive oral lichen planus treated with upadacitinib.JAAD case reports · 2026Article
- Xanthogranuloma disseminatum: Successfully treated with statins followed by upadacitinib.JAAD case reports · 2026Article
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology.Medicina (Kaunas, Lithuania) · 2026Review
- JAK1 Inhibition with Upadacitinib in a Patient with Refractory Severe Chronic Spontaneous Urticaria and Concomitant Rheumatoid Arthritis: Complete Resolution of Urticaria and Remission of Rheumatoid Arthritis.Acta dermato-venereologica · 2025Article
- Current Treatments and Future Directions for Hidradenitis Suppurativa: a Narrative Review of Completed and Ongoing Phase 3 Clinical Trials of Biologic Therapies.Dermatology and therapy · 2025Review
- Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review.Journal of clinical medicine · 2025Review
- Upadacitinib Coadministered with Methylprednisolone for Effective Treatment of SJS/TEN Overlap Syndrome: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, has gained FDA approval for conditions such as rheumatoid arthritis and atopic dermatitis. Emerging studies suggest its potential for off-label use in various dermatological disorders. This review systematically explores the off-label dermatological applications of upadacitinib. We conducted a comprehensive literature search across MEDLINE, EMBASE, SCOPUS, and ClinicalTrials.gov. Studies on alopecia areata, hidradenitis suppurativa, vitiligo, and other conditions were included. The review identified two randomized controlled trials (RCTs) evaluating upadacitinib's efficacy in hidradenitis suppurativa and vitiligo. Both trials demonstrated promising improvements in clinical outcomes, though some results were not statistically significant. Additionally, case reports and series highlight its efficacy in alopecia areata and lichen planus. These findings suggest upadacitinib as a viable option for refractory dermatological conditions. However, the limited sample sizes and short follow-up periods underscore the need for further large-scale, long-term studies.
Indexed as
Identifiers
39920358What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.